Broadly Neutralizing Antibodies for HIV Prevention: a Comprehensive Review and Future Perspectives

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2024 Apr 30

PMID 38687039

Authors

Sharana Mahomed

Affiliations

Soon will be listed here.

Abstract

SUMMARYThe human immunodeficiency virus (HIV) epidemic remains a formidable global health concern, with 39 million people living with the virus and 1.3 million new infections reported in 2022. Despite anti-retroviral therapy's effectiveness in pre-exposure prophylaxis, its global adoption is limited. Broadly neutralizing antibodies (bNAbs) offer an alternative strategy for HIV prevention through passive immunization. Historically, passive immunization has been efficacious in the treatment of various diseases ranging from oncology to infectious diseases. Early clinical trials suggest bNAbs are safe, tolerable, and capable of reducing HIV RNA levels. Although challenges such as bNAb resistance have been noted in phase I trials, ongoing research aims to assess the additive or synergistic benefits of combining multiple bNAbs. Researchers are exploring bispecific and trispecific antibodies, and fragment crystallizable region modifications to augment antibody efficacy and half-life. Moreover, the potential of other antibody isotypes like IgG3 and IgA is under investigation. While promising, the application of bNAbs faces economic and logistical barriers. High manufacturing costs, particularly in resource-limited settings, and logistical challenges like cold-chain requirements pose obstacles. Preliminary studies suggest cost-effectiveness, although this is contingent on various factors like efficacy and distribution. Technological advancements and strategic partnerships may mitigate some challenges, but issues like molecular aggregation remain. The World Health Organization has provided preferred product characteristics for bNAbs, focusing on optimizing their efficacy, safety, and accessibility. The integration of bNAbs in HIV prophylaxis necessitates a multi-faceted approach, considering economic, logistical, and scientific variables. This review comprehensively covers the historical context, current advancements, and future avenues of bNAbs in HIV prevention.

Citing Articles

Contrastive Learning Enables Epitope Overlap Predictions for Targeted Antibody Discovery.

Holt C, Janke A, Amlashi P, Jamieson P, Marinov T, Georgiev I bioRxiv. 2025; .

PMID: 40060439 PMC: 11888244. DOI: 10.1101/2025.02.25.640114.

Diphtheria antitoxin treatment: from pioneer to neglected.

Grandiere Perez L, Brisse S Mem Inst Oswaldo Cruz. 2025; 120:e240214.

PMID: 39841756 PMC: 11752783. DOI: 10.1590/0074-02760240214.

Interventions during Early Infection: Opening a Window for an HIV Cure?.

Hiner C, Mueller A, Su H, Goldstein H Viruses. 2024; 16(10).

PMID: 39459922 PMC: 11512236. DOI: 10.3390/v16101588.

Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines.

Lin L, Gantner P, Li S, Su B, Moog C J Infect Dis. 2024; 231(1):e1-e9.

PMID: 39302695 PMC: 11793060. DOI: 10.1093/infdis/jiae464.

References

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

Ma J, Drossard J, Lewis D, Altmann F, Boyle J, Christou P . Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8):1106-20. DOI: 10.1111/pbi.12416. View

Beckford-Vera D, Flavell R, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C . First-in-human immunoPET imaging of HIV-1 infection using Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022; 13(1):1219. PMC: 8907355. DOI: 10.1038/s41467-022-28727-5. View

Gong S, Ruprecht R . Immunoglobulin M: An Ancient Antiviral Weapon - Rediscovered. Front Immunol. 2020; 11:1943. PMC: 7432194. DOI: 10.3389/fimmu.2020.01943. View

Agosto L, Uchil P, Mothes W . HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol. 2015; 23(5):289-95. PMC: 4417442. DOI: 10.1016/j.tim.2015.02.003. View

Locke K, Maneval D, LaBarre M . ENHANZE drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019; 26(1):98-106. PMC: 6394283. DOI: 10.1080/10717544.2018.1551442. View

Miner M, Corey L, Montefiori D . Broadly neutralizing monoclonal antibodies for HIV prevention. J Int AIDS Soc. 2021; 24 Suppl 7:e25829. PMC: 8606861. DOI: 10.1002/jia2.25829. View

Nishimura Y, Otagiri M, Yuki M, Shimizu M, Inoue J, Moriya S . Division of functional roles for termite gut protists revealed by single-cell transcriptomes. ISME J. 2020; 14(10):2449-2460. PMC: 7490689. DOI: 10.1038/s41396-020-0698-z. View

10.

Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C . A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol. 2009; 184(1):359-68. PMC: 4272871. DOI: 10.4049/jimmunol.0902278. View

11.

McFarland E, Cunningham C, Muresan P, Capparelli E, Perlowski C, Morgan P . Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021; 224(11):1916-1924. PMC: 8643399. DOI: 10.1093/infdis/jiab229. View

12.

Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O . Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2009; 65(5):657-61. DOI: 10.1111/j.1398-9995.2009.02280.x. View

13.

Kerwin B, Bennett C, Brodsky Y, Clark R, Floyd J, Gillespie A . Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. J Pharm Sci. 2019; 109(1):233-246. PMC: 6941225. DOI: 10.1016/j.xphs.2019.07.009. View

14.

Karpas A, Hill F, Youle M, Cullen V, Gray J, Byron N . Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1988; 85(23):9234-7. PMC: 282713. DOI: 10.1073/pnas.85.23.9234. View

15.

Doessegger L, Banholzer M . Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015; 4(7):e39. PMC: 4524952. DOI: 10.1038/cti.2015.14. View

16.

Sobieszczyk M, Mannheimer S, Paez C, Yu C, Gamble T, Theodore D . Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase.... Lancet HIV. 2023; 10(10):e653-e662. PMC: 10629933. DOI: 10.1016/S2352-3018(23)00140-6. View

17.

Graham B, Ambrosino D . History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015; 10(3):129-34. PMC: 4437582. DOI: 10.1097/COH.0000000000000154. View

18.

Takuva S, Karuna S, Juraska M, Rudnicki E, Edupuganti S, Anderson M . Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. J Acquir Immune Defic Syndr. 2021; 89(4):405-413. PMC: 9555144. DOI: 10.1097/QAI.0000000000002892. View

19.

Prabhakaran M, Narpala S, Andrews S, OConnell S, Lin C, Coates E . A sensitive method to quantify HIV-1 antibodies in mucosal samples. J Immunol Methods. 2021; 491:112995. DOI: 10.1016/j.jim.2021.112995. View

20.

Saifuddin M, Hedayati T, Atkinson J, Holguin M, Parker C, Spear G . Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol. 1997; 78 ( Pt 8):1907-11. DOI: 10.1099/0022-1317-78-8-1907. View